- Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeoverWith the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.BioSpace · 10d ago↗ source
- Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorMerck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.BioSpace · 10d ago↗ source
- STAT+: Pharmalittle: We’re reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and moreKalshi, one of the world’s largest prediction market exchanges, plans to take bets on clinical trials and regulatory approvals